KIAA0090 Inhibitors
ER membrane protein complex subunit 1 (KIAA0090) Inhibitors are a diverse set of chemical compounds that decrease the functional activity of KIAA0090 through various mechanisms related to protein processing and trafficking within the endoplasmic reticulum (ER). Tunicamycin and Brefeldin A target fundamental processes in protein glycosylation and ER-to-Golgi trafficking, respectively, both crucial for the proper functioning of the EMC complex; hence, their inhibition can lead to decreased functional activity of KIAA0090 by disrupting the maturation and transport of proteins in which KIAA0090 plays a role. Similarly, Thapsigargin and Cyclopiazonic acid, by disturbing ER calcium homeostasis, and DTT, throughreducing disulfide bonds, create an environment that hampers KIAA0090's role in protein folding and assembly. Compounds like Eeyarestatin I and MG-132 block ER-associated degradation and proteasome activity, respectively, leading to an accumulation of misfolded proteins within the ER that could indirectly diminish KIAA0090's functional capacity in quality control. Additionally, the histone deacetylase inhibitor, Suberoylanilide hydroxamic acid, by altering expression patterns of EMC-associated factors, and Geldanamycin, by destabilizing Hsp90 client proteins, can indirectly interfere with KIAA0090's function in the ER.
The action of β-Lapachone in promoting oxidative stress and Puromycin by causing premature termination of protein synthesis adds further stress to the ER's protein-folding environment, which may indirectly impede KIAA0090's involvement in these processes. Azaspiracid, with its ability to disrupt calcium homeostasis, can also compromise the protein maturation roles associated with KIAA0090. Collectively, these chemical inhibitors, through their targeted effects on cellular processes and pathways, contribute to the indirect inhibition of KIAA0090 functions without directly modulating its expression or activity. Their mechanisms of action reveal the interconnected nature of intracellular pathways and the delicate balance required for KIAA0090 to effectively contribute to protein homeostasis within the ER.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $169.00 $299.00 | 66 | |
Tunicamycin inhibits N-linked glycosylation in the ER, a process essential for proper folding and function of many proteins. Since KIAA0090 is integral to the ER membrane protein complex (EMC), impairment of glycosylation can indirectly lead to its functional inhibition. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $30.00 $52.00 $122.00 $367.00 | 25 | |
Brefeldin A disrupts ER-to-Golgi transport by inhibiting ADP-ribosylation factor. As EMC1 is involved in protein folding and trafficking within the ER, this disruption can indirectly diminish KIAA0090's role in these processes. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
Thapsigargin inhibits the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA), leading to depletion of ER calcium stores. This calcium imbalance can negatively affect ER functions, including those dependent on KIAA0090-associated processes. | ||||||
Cyclopiazonic Acid | 18172-33-3 | sc-201510 sc-201510A | 10 mg 50 mg | $173.00 $612.00 | 3 | |
Cyclopiazonic acid is an inhibitor of SERCA, leading to a decrease in ER calcium levels and potential indirect inhibition of KIAA0090 functions related to calcium-dependent processing of proteins. | ||||||
Eeyarestatin I | 412960-54-4 | sc-358130B sc-358130 sc-358130A sc-358130C sc-358130D sc-358130E | 5 mg 10 mg 25 mg 50 mg 100 mg 500 mg | $112.00 $199.00 $347.00 $683.00 $1336.00 $5722.00 | 12 | |
Eeyarestatin I inhibits the ER-associated degradation (ERAD) pathway, which could lead to increased misfolded proteins within the ER and potentially burden the EMC, indirectly inhibiting the function of KIAA0090. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
MG-132 is a proteasome inhibitor that can lead to the accumulation of misfolded proteins within the ER, indirectly affecting KIAA0090's role in managing protein quality control and proper folding. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $130.00 $270.00 | 37 | |
SAHA is a histone deacetylase inhibitor that can influence gene expression profiles. By altering the expression of chaperones or co-factors associated with the EMC, it could indirectly affect the functional activity of KIAA0090. | ||||||
Geldanamycin | 30562-34-6 | sc-200617B sc-200617C sc-200617 sc-200617A | 100 µg 500 µg 1 mg 5 mg | $38.00 $58.00 $102.00 $202.00 | 8 | |
Geldanamycin binds to heat shock protein 90 (Hsp90) and inhibits its function. By destabilizing client proteins of Hsp90 that may interact or co-operate with the EMC, it could indirectly inhibit the functional activity of KIAA0090. | ||||||
β-Lapachone | 4707-32-8 | sc-200875 sc-200875A | 5 mg 25 mg | $110.00 $450.00 | 8 | |
β-Lapachone generates reactive oxygen species (ROS) within cells, which can lead to oxidative stress. This stress can damage proteins and disrupt normal ER function, potentially diminishing KIAA0090 activity related to protein folding and assembly. | ||||||
Puromycin dihydrochloride | 58-58-2 | sc-108071 sc-108071B sc-108071C sc-108071A | 25 mg 250 mg 1 g 50 mg | $40.00 $210.00 $816.00 $65.00 | 394 | |
Puromycin causes premature chain termination during protein synthesis, leading to the production of incomplete proteins. This can increase the load of misfolded proteins in the ER, indirectly inhibiting the functional activity of KIAA0090 by overwhelming the EMC's capacity. | ||||||